DexCom(US:DXCM) Prnewswire·2025-12-05 20:30Core Viewpoint - A class action securities lawsuit has been filed against DexCom, Inc. alleging securities fraud that affected investors between January 8, 2024, and September 17, 2025 [1] Group 1: Allegations of the Lawsuit - The lawsuit claims that DexCom made unauthorized material design changes to its glucose monitoring products, the G6 and G7, without FDA approval [2] - It is alleged that these design changes made the G6 and G7 less reliable, posing a material health risk to users who depend on these devices for accurate glucose readings [2] - The complaint asserts that the enhancements to the G7 and its reliability, accuracy, and functionality were overstated by the defendants [2] - Defendants allegedly downplayed the severity of the issues and health risks associated with the altered G7 devices [2] - The lawsuit indicates that these actions exposed DexCom to increased regulatory scrutiny and potential legal, reputational, and financial harm [2] - As a result, the public statements made by the defendants were claimed to be materially false and misleading [2] Group 2: Next Steps for Affected Investors - Investors who suffered losses in DexCom during the specified timeframe have until December 26, 2025, to request to be appointed as lead plaintiff [3] - Participation in the lawsuit does not require serving as a lead plaintiff, and class members may be entitled to compensation without any out-of-pocket costs [3] Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and has extensive expertise in complex securities litigation [4] - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the U.S. [4]